{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:08:41Z","timestamp":1791353321388,"version":"4.3.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1038\/sj.bjc.6600139","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T15:08:05Z","timestamp":1031152085000},"page":"1297-1302","source":"Crossref","is-referenced-by-count":218,"title":["How to calculate the dose of chemotherapy"],"prefix":"10.1038","volume":"86","author":[{"given":"H","family":"Gurney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,4,16]]},"reference":[{"key":"BF6600139_CR1","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2000.18.3.562","volume":"18","author":"J Alexandre","year":"2000","unstructured":"Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J, Viens P, Faivre S, Chahine A, Spielman M, Bensmaine A, Marty M, Mahjoubi M, Cvitkovic E (2000) Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18: 562\u2013573","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR2","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0140-6736(00)02841-5","volume":"356","author":"J Berch","year":"2000","unstructured":"Berch J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356: 1384\u20131391","journal-title":"Lancet"},{"key":"BF6600139_CR3","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1200\/JCO.1999.17.8.2355","volume":"17","author":"JF Bishop","year":"1999","unstructured":"Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R (1999) Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front line therapy in untreated metastatic breast cancer. J Clin Oncol 17: 2355\u20132364","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","volume":"90","author":"DR Budman","year":"1998","unstructured":"Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei III E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90: 1205\u20131211","journal-title":"J Natl Cancer Inst"},{"key":"BF6600139_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/1097-0142(19820701)50:1<18::AID-CNCR2820500105>3.0.CO;2-J","volume":"50","author":"JT Carpenter","year":"1982","unstructured":"Carpenter JT, Maddox WA, Laws HL, Wirtschafter DD, Soong SJ (1982) Favorable factors in the adjuvant therapy of breast cancer. Cancer 50: 18\u201323","journal-title":"Cancer"},{"key":"BF6600139_CR6","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1200\/JCO.1998.16.6.2188","volume":"16","author":"SM Chang","year":"1998","unstructured":"Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold Jr SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados MD (1998) Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 16: 2188\u20132194","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR7","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJM197411072911903","volume":"291","author":"EP Cortes","year":"1974","unstructured":"Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, Senn H, Bank A, Glidewell O (1974) Amputation and adriamycin in primary osteosarcoma. N Engl I Med 291: 998\u20131000","journal-title":"N Engl I Med"},{"key":"BF6600139_CR8","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2001.19.17.3733","volume":"19","author":"FE de Jongh","year":"2001","unstructured":"de Jongh FE, Verweij L, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A (2001) Body-Surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19: 3733\u20133739","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR9","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930\u2013934","DOI":"10.1016\/S0140-6736(98)03301-7"},{"key":"BF6600139_CR10","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248\u20132253","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR11","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516\u20131525","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","volume":"17","author":"E Gaemlin","year":"1999","unstructured":"Gaemlin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17: 1105\u20131110","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1440-1746.1996.tb00007.x","volume":"11","author":"J George","year":"1996","unstructured":"George J, Byth K, Farrell GC (1996) Influence of clinicopathological variables on CYP protein. J Gastroenterol Hepatol 11: 33\u201339","journal-title":"J Gastroenterol Hepatol"},{"key":"BF6600139_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/oxfordjournals.annonc.a058348","volume":"4","author":"H Gurney","year":"1993","unstructured":"Gurney H, Dodwell D, Thatcher N, Tattersall MHN (1993) Escalating drug delivery in cancer chemotherapy: A review of concepts and practice \u2013 part 1. Annals Oncol 4: 23\u201334","journal-title":"Annals Oncol"},{"key":"BF6600139_CR15","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","volume":"14","author":"H Gurney","year":"1996","unstructured":"Gurney H (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 14: 2590\u20132611","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR16","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.1998.16.7.2299","volume":"16","author":"HP Gurney","year":"1998","unstructured":"Gurney HP, Ackland S, Gebski V, Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16: 2299\u20133004","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR17","first-page":"305","volume":"20","author":"H Gurney","year":"2001","unstructured":"Gurney H, Ackland S, Liddle C, Dunleavey R, Rivory L, Farlow D, Evans S, Garg M, Gebski V, Collins M, Farrell G (2001) Determining the drug elimination phenotype: Hepatic sestamibi scan and midazolam clearance as in vivo tests for drug metabolism and biliary elimination. Proc Am Soc Clin Oncol 20: 305 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6600139_CR18","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1200\/JCO.1997.15.5.1844","volume":"15","author":"A Horwich","year":"1997","unstructured":"Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council\/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844\u20131852","journal-title":"J Clin Oncol"},{"issue":"3","key":"BF6600139_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/10428199209053626","volume":"7","author":"D Hovgaard","year":"1992","unstructured":"Hovgaard D, Nissen NI (1992) A phase I\/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas. Leuk Lymphoma 7: 3 217\u2013224","journal-title":"Leuk Lymphoma"},{"key":"BF6600139_CR20","doi-asserted-by":"crossref","unstructured":"International Germ Cell Consensus Classification (1997) A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594\u2013603","DOI":"10.1200\/JCO.1997.15.2.594"},{"key":"BF6600139_CR21","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1074\/jbc.M109326200","volume":"277","author":"HR Kast","year":"2002","unstructured":"Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA (2002) Regulation of multidrug resistance-associated protein 2 (MRP2;ABCC2) by the nuclear receptors PXR, FXR, and CAR. J Biol Chem 277: 2908\u20132915","journal-title":"J Biol Chem"},{"key":"BF6600139_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","volume":"21","author":"PE Kintzel","year":"1995","unstructured":"Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21: 33\u201364","journal-title":"Cancer Treat Rev"},{"key":"BF6600139_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"4","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 4: 383\u2013391","journal-title":"Nat Genet"},{"key":"BF6600139_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JCO.2002.20.1.81","volume":"20","author":"RHJ Mathijssen","year":"2002","unstructured":"Mathijssen RHJ, Verweij J, Maja JA, de Jonge MJA, Nooter K, Stoter G, Sparreboom A (2002) Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 20: 81\u201387","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"BF6600139_CR25","first-page":"274","volume":"52","author":"OR McIntyre","year":"1978","unstructured":"McIntyre OR, Leone L, Pajak TF (1978) The use of intravenous melphalan (L-PAM) in the treatment of multiple myeloma. Blood 52: Suppl 1 274","journal-title":"Blood"},{"issue":"11","key":"BF6600139_CR26","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.bjc.6690594","volume":"80","author":"P Poikenen","year":"1999","unstructured":"Poikenen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Luecocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80: 11 1763\u20131766","journal-title":"Br J Cancer"},{"key":"BF6600139_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/bjc.1992.55","volume":"65","author":"EM Rankin","year":"1992","unstructured":"Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, Cruickshank D, Davis J, Duncan ID, Fullerton W, Habeshaw T, Kennedy J, Kennedy R, Kitchener H, MacLean A, Paul J, Reed N, Sarker T, Soukop M, Swapp GH, Symonds RP (1992) A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 65: 275\u2013281","journal-title":"Br J Cancer"},{"key":"BF6600139_CR28","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.1991.9.8.1480","volume":"9","author":"MJ Ratain","year":"1991","unstructured":"Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9: 1480\u20131486","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR29","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1200\/JCO.1998.16.7.2297","volume":"16","author":"MJ Ratain","year":"1998","unstructured":"Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?. J Clin Oncol 16: 2297\u20132298","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0140-6736(00)02503-4","volume":"356","author":"MV Relling","year":"2000","unstructured":"Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG, Evans WE (2000) Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356: 285\u2013290","journal-title":"Lancet"},{"issue":"5","key":"BF6600139_CR31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/1097-0142(19840301)53:5<1029::AID-CNCR2820530503>3.0.CO;2-Z","volume":"53","author":"MK Samson","year":"1984","unstructured":"Samson MK, Rivkin SE, Jones SE, Costanzi JJ, LoBuglio AF, Stephens RL, Gehan EA, Cummings GD (1984) Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 53: 5 1029\u20131035","journal-title":"Cancer"},{"key":"BF6600139_CR32","first-page":"306","volume":"20","author":"AF Schott","year":"2001","unstructured":"Schott AF, Taylor LB, Baker L (2001) Individualized chemotherapy dosing based on metabolic phenotype. Proc Am Soc Clin Oncol 20: 306 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"7","key":"BF6600139_CR33","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1200\/JCO.1998.16.7.2392","volume":"16","author":"JH Silber","year":"1998","unstructured":"Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR (1998) First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 16: 7 2392\u20132400","journal-title":"J Clin Oncol"},{"key":"BF6600139_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJM200004133421501","volume":"342","author":"EA Stadtmauer","year":"2000","unstructured":"Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342: 1069\u20131076","journal-title":"N Engl J Med"},{"key":"BF6600139_CR35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/87912","volume":"7","author":"TW Synold","year":"2001","unstructured":"Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7: 584\u2013590","journal-title":"Nat Med"},{"key":"BF6600139_CR36","first-page":"1137","volume":"297","author":"M Tanabe","year":"2001","unstructured":"Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137\u20131143","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6600139_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/BF02353474","volume":"24","author":"SA Wrighton","year":"1996","unstructured":"Wrighton SA, VandenBranden M, Ring BJ (1996) The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 24: 461\u2013473","journal-title":"J Pharmacokinet Biopharm"},{"key":"BF6600139_CR38","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00008571-200110000-00003","volume":"7","author":"J Zhang","year":"2001","unstructured":"Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson Jr JR, Schuetz EG, Boguski MS (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 7: 555\u2013572","journal-title":"Pharmacogenetics"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6600139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600139","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:41:09Z","timestamp":1684413669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6600139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["BF6600139"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6600139","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}